Changing the order of treatments given to breast cancer patients could reduce side effects and improve outcomes, according to an Imperial study.
Jul 28, 2022
0
79
The International Agency for Research on Cancer (IARC) recently classified occupational exposure as a firefighter as "carcinogenic," changing the previous classification of "possibly carcinogenic." The reclassification came ...
Jul 20, 2022
0
126
Patients with advanced kidney cancer who received a new combination treatment reported health-related quality of life outcomes that were either similar or improved, compared to patients who received standard first-line therapy, ...
Jun 24, 2022
0
80
A study co-led by the Universities of Oxford, Birmingham and Southampton and the U.K. Health Security Agency (UKHSA), published in Lancet Oncology today by the U.K. Coronavirus Cancer Evaluation Project, has found that while ...
May 23, 2022
0
61
More than a third of cancers in the UK are discovered after patients are rushed to hospital, one of the highest rates in comparable high-income countries, finds a new study led by UCL researchers.
Apr 8, 2022
0
64
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, ...
Jan 17, 2022
0
75
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by ...
Nov 25, 2021
0
151
Men who inherit an increased risk of cancer through "Lynch syndrome" could benefit from regular PSA testing from age 40 to detect early signs of prostate cancer, researchers believe.
Oct 19, 2021
0
57
Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new ...
Sep 20, 2021
0
143
Talazoparib, a new precision drug, can keep cancer in check in some men with advanced prostate cancer who have run out of options, a phase II clinical trial shows.
Aug 23, 2021
0
129
